ERBB2 and breast carcinoma: Subsequent to the FAKTION publication, the phase 3 IPATunity130 trial found no progression-free survival benefit from adding the AKT inhibitor ipatasertib to paclitaxel in patients with PI3K/AKT/PTEN pathway-altered ER-positive, HER2-negative advanced breast cancer.